Table 2.
Metabolites significantly associated with HTOT-BMD
| Metabolites | Class | m/z | RT | VIP | β | q-value |
|---|---|---|---|---|---|---|
| 2-Methyl-3-hydroxybutyric acid | Fatty acids | 182.08 | 305.16 | 2.80 | 0.04 | 0.995 |
| Dodecanoic acid | Fatty acids | 199.17 | 40.28 | 1.86 | -0.16 | 0.032 |
| Myristic acid | Fatty acids | 227.20 | 38.35 | 1.31 | -0.21 | < 0.001 |
| Arachidonic acid | Fatty acids | 303.23 | 193.35 | 0.71 | 0.23 | < 0.001 |
| PC(18:0/18:1(9Z)) | Glycerophospholipids | 810.60 | 155.26 | 2.40 | 0.01 | 0.995 |
| PC(16:0/16:0) | Glycerophospholipids | 734.56 | 161.48 | 2.32 | 0.02 | 0.995 |
| LysoPC(18:0) | Glycerophospholipids | 568.34 | 192.08 | 2.16 | 0.00 | 0.995 |
| D-mannose | Organic compounds | 145.05 | 287.73 | 2.00 | -0.01 | 0.995 |
| Methoxyacetic acid | Organic compounds | 198.10 | 282.52 | 2.24 | 0.06 | 0.995 |
| Uracil | Organic compounds | 113.03 | 156.80 | 2.11 | -0.02 | 0.995 |
| L-carnitine | Organic compounds | 323.22 | 325.98 | 2.01 | -0.01 | 0.995 |
| Alpha-D-glucose | Organic compounds | 179.05 | 283.53 | 0.57 | -0.16 | 0.030 |
| Glutaraldehyde | Organic compounds | 123.04 | 22.53 | 2.10 | 0.01 | 0.995 |
| Paraxanthine | Organic compounds | 217.02 | 25.36 | 0.51 | -0.21 | < 0.001 |
| Glycolate | Organic compounds | 135.03 | 326.78 | 2.09 | -0.02 | 0.995 |
| D-proline | Peptides | 116.07 | 298.63 | 1.54 | 0.17 | 0.032 |
| Phenylalanyl-cysteine | Peptides | 310.13 | 280.97 | 0.74 | -0.20 | 0.002 |
| Glycocholic acid | Sterol lipids | 464.31 | 175.03 | 2.71 | -0.07 | 0.995 |
| Cortisone | Sterol lipids | 361.20 | 36.25 | 2.44 | 0.02 | 0.995 |
| Glycochenodeoxycholate | Sterol lipids | 414.30 | 202.59 | 0.09 | 0.20 | 0.002 |
Abbreviations: HTOT-BMD, total hip bone mineral density; β-regression coefficient of the association between metabolites and HTOT-BMD; m/z, mass-to-charge ratios; q-value, p-value adjusted by false discovery rate; RT, retention time; VIP, variable importance in projection.